Lastin (Azelastine Hydrochloride)

Azelastine blocks histamine H1 receptors on mast cells in the eye and stabilises those cells, preventing the release of histamine and other inflammatory mediators. This action reduces vasodilation, vascular permeability and the resulting allergic inflammation.

The dosing regimen for Lastin is determined by the prescribing clinician based on the patient’s condition and response. Typical practice involves one or two drops per affected eye, but the exact amount and frequency should follow the prescriber’s instructions.

Safety data for azelastine in pregnancy and lactation are limited. It should be used only if the potential therapeutic benefit justifies any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To order Lastin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

Lastin contains azelastine, a selective H1‑receptor antagonist with mast‑cell stabilising properties, offering rapid symptom relief and a relatively low incidence of systemic side effects compared with some older antihistamine eye drops. Its dual action can provide more comprehensive control of allergic eye symptoms.

Store Lastin at room temperature, ideally below 25 °C, in its original packaging. Protect the container from direct light, moisture and extreme temperature fluctuations. Keep the bottle tightly closed when not in use to maintain sterility.

Lastin is applied as an eye drop. The patient should wash hands, tilt the head back slightly, pull down the lower eyelid to form a pocket, and instill the prescribed number of drops into the conjunctival sac. Avoid touching the tip of the bottle to the eye or any surface.

Serious risks, although rare, include severe allergic reactions such as anaphylaxis, corneal ulceration, significant increases in intra‑ocular pressure, and vision loss. Patients should seek immediate medical attention if they experience intense eye pain, sudden vision changes, or signs of a systemic allergic response.

Lastin should not be used by individuals with known hypersensitivity to azelastine, other antihistamines, or any excipients in the formulation. It is also contraindicated in patients with active ocular infections until the infection has been adequately treated.